

# Gabrielle Couchy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11366234/publications.pdf>

Version: 2024-02-01

58  
papers

9,247  
citations

126907

33  
h-index

144013

57  
g-index

59  
all docs

59  
docs citations

59  
times ranked

12365  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	21.4	1,372
2	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. <i>Nature Genetics</i> , 2012, 44, 694-698.	21.4	1,229
3	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. <i>Hepatology</i> , 2008, 47, 1955-1963.	7.3	634
4	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. <i>Hepatology</i> , 2007, 46, 740-748.	7.3	554
5	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	3.7	525
6	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. <i>Nature</i> , 2009, 457, 200-204.	27.8	437
7	Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. <i>Hepatology</i> , 2009, 50, 481-489.	7.3	394
8	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	21.4	387
9	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	3.7	354
10	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	1.3	302
11	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	1.3	290
12	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. <i>Clinical Cancer Research</i> , 2015, 21, 1329-1339.	7.0	250
13	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	16.8	240
14	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. <i>Nature Communications</i> , 2017, 8, 1315.	12.8	228
15	Genotype-phenotype correlation of CTNNB1 mutations reveals different $\beta$ -catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	7.3	222
16	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	8.5	218
17	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	1.3	141
18	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	7.3	129

#	ARTICLE	IF	CITATIONS
19	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	12.8	118
20	Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and pointâ€mutant Î²â€catenin. <i>Hepatology</i> , 2016, 64, 1587-1605.	7.3	92
21	The Î²-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. <i>Journal of Hepatology</i> , 2008, 49, 61-71.	3.7	87
22	Ploidy spectrum: a new marker in HCC classification. <i>Gut</i> , 2020, 69, 355-364.	12.1	82
23	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	1.9	72
24	Hepatocyte nuclear factor 1Î± suppresses steatosis-associated liver cancer by inhibiting PPARÎ³ transcription. <i>Journal of Clinical Investigation</i> , 2017, 127, 1873-1888.	8.2	58
25	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2017, 23, 4364-4375.	7.0	57
26	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib â€ a multicentric retrospective analysis. <i>Acta OncolÃ³gica</i> , 2014, 53, 103-112.	1.8	45
27	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. <i>Modern Pathology</i> , 2016, 29, 43-50.	5.5	45
28	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	3.7	44
29	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	7.3	43
30	TGF-Î²1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking. <i>European Journal of Cell Biology</i> , 2016, 95, 503-512.	3.6	41
31	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. <i>Acta OncolÃ³gica</i> , 2018, 57, 498-508.	1.8	41
32	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncolmmunology</i> , 2013, 2, e27090.	4.6	39
33	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	1.9	37
34	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 160-178.	7.3	36
35	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	10.7	36
36	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	1.9	34

#	ARTICLE	IF	CITATIONS
37	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. <i>Molecular Therapy</i> , 2016, 24, 660-661.	8.2	33
38	Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease. <i>Journal of Hepatology</i> , 2016, 65, 552-559.	3.7	32
39	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	3.7	31
40	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , 2014, 53, 1413-1422.	1.8	30
41	Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.	2.5	23
42	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methyomes. <i>Hepatology</i> , 2021, 74, 816-834.	7.3	20
43	Metalloproteinase meprin $\beta$ regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. <i>Oncotarget</i> , 2017, 8, 7839-7851.	1.8	20
44	Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	12.1	17
45	MicroRNAs Targeting HIF-2 $\beta$ , VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2 $\beta$ Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3099.	3.7	16
46	Characterization of a novel PXR isoform with potential dominant-negative properties. <i>Journal of Hepatology</i> , 2014, 61, 609-616.	3.7	15
47	Focal $\beta$ -catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas. <i>Histopathology</i> , 2017, 71, 989-993.	2.9	14
48	Malignant transformation of a $\beta$ -catenin inflammatory adenoma due to an S45 $\beta$ -catenin-activating mutation present 12 years before. <i>Human Pathology</i> , 2017, 62, 122-125.	2.0	13
49	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	1.8	12
50	Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 266-273.	1.9	11
51	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 323-332.	3.7	11
52	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1554.	3.7	9
53	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	1.9	9
54	AAV2 and Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2016, 27, 211-213.	2.7	8

#	ARTICLE	IF	CITATIONS
55	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	2.5	5
56	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246.	1.9	4
57	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. Clinical Genitourinary Cancer, 2019, 17, e909-e912.	1.9	1
58	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. Kidney Cancer, 2020, 4, 139-149.	0.4	0